IDH1 and glioblastoma: To identify predictive features and establish an integrative method to distinguish TMZ responder and non-responder before TMZ chemotherapy, we cultured a panel of GSCs derived from newly diagnosed treatment-naïve IDH-wt GBM patients and analyzed genomic traits and drug screening data of their early passages.